Latest news with #Divi'sLaboratories
Business Standard
a day ago
- Business
- Business Standard
Divi's Laboratories consolidated net profit rises 26.74% in the June 2025 quarter
Sales rise 13.79% to Rs 2410.00 croreNet profit of Divi's Laboratories rose 26.74% to Rs 545.00 crore in the quarter ended June 2025 as against Rs 430.00 crore during the previous quarter ended June 2024. Sales rose 13.79% to Rs 2410.00 crore in the quarter ended June 2025 as against Rs 2118.00 crore during the previous quarter ended June EndedJun. 2025Jun. 2024% 14 OPM %30.2529.37 -PBDT845.00701.00 21 PBT733.00604.00 21 NP545.00430.00 27 Powered by Capital Market - Live News
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Divi's Labs falls 4% after Q1 miss, analysts trim estimates; check details
Divi's Laboratories share price today: Shares of Hyderabad-based pharmaceutical company Divi's Laboratories continued their downtrend, falling nearly 4 per cent to hit a low of ₹5,960.5 on the NSE in Thursday's intraday trade. In the last two trading sessions, the stock has tanked 7 per cent after the company reported mixed performance in the June 2025 quarter (Q1FY26). The stock has tumbled around 16 per cent from its 52-week low of ₹7,071.5 touched on July 8, 2025. At 1:15 PM, Divi's Lab stock was trading 2.1 per cent lower at ₹6,004.5 per share on the NSE. In comparison, NSE Nifty50 was down 0.72 per cent at 24,39.5 levels. The market capitalisation of the company stood at ₹1.59 trillion. Divi's Laboratories Q1 results Divi's Laboratories reported a 14 per cent year-on-year (Y-o-Y) jump in revenue at ₹2,410 crore in Q1FY26, compared to ₹2,118 crore in the year-ago period. The company's net profit grew 27 per cent Y-o-Y to ₹545 crore from ₹430 crore last year. Operating profit (Ebitda) rose 16.3 per cent to ₹756 crore, against ₹650 crore in the same quarter last year. Operating margin expanded by 70 basis points to 31.4 per cent from 30.7 per cent. Divi's Laboratories Q1 results analysis - Motilal Oswal Financial Services Analysts at MOSFL said that Divi's Labs reported revenue, Ebitda, and PAT below their estimates, affected by lower traction in the generics segment and increased operational expenditure. However, Q1FY26 was the seventh consecutive quarter of robust YoY growth in earnings. "Custom synthesis business has been witnessing strong growth momentum, driven by robust engagement across clinical phases and at the commercial stage. Divi's continues to build technology platforms and add capacities to support manufacturing requirements for innovator customers," the brokerage said. Additionally, the company is making efforts to sustain market share in the generics API space. It is also working on the manufacturing value chain to keep profitability intact. MOFSL slashed their earnings estimates by 8 per cent and 6 per cent for FY26 and FY27, respectively, factoring in the current pricing pressure in the generics segment, incremental operational expenditure related to new projects, and revenue being back-ended. "We estimate 20 per cent earnings CAGR over FY25-27 on the back of improved business prospects in the CS segment as certain contracts are currently undergoing pilot study/qualification and subsequently expected to scale up to the commercial level. Notably, peptide is expected to be the next breakthrough opportunity for DIVI. However, the current valuation leaves limited upside," MOFSL said in a note. The brokerage maintained a 'Neutral' rating on the stock with a target price of ₹6,320. InCred Equities According to analysts at InCred Equities, Divi's Laboratories posted a healthy Q1FY26 performance but missed on the margin front. The custom synthesis business grew by 23 per cent Y-o-Y while the generics segment was weak. "The Kakinada plant aids in backwards integration, and its units 1 and 2 are freed for GMP manufacturing. FY26F capital expenditure (capex) revised to ₹20 billion from ₹14 billion earlier," the brokerage said. InCred Equities trimmed their FY26F/27F estimates to factor in slower-than-expected growth in generics and margin improvement. The brokerage maintained an 'Add' rating on the stock with a target price of ₹6,800 (₹7,100 earlier), noting that Divi's premium valuation (significantly above SD+1 level) is likely to remain buoyant, underpinned by structural tailwinds and margin expansion. InCred highlighted that any slowdown in the custom synthesis business could pose downside risks.
The Hindu
3 days ago
- Business
- The Hindu
Divi's Q1 net up 27% YoY to ₹545 crore, slips sequentially
Active pharmaceutical ingredient (API) manufacturer Divi's Laboratories reported consolidated net profit for June quarter increased nearly 27% to ₹545 crore compared with ₹430 crore a year earlier. The net profit came on an almost 14% increase in the revenue from operations to ₹2,410 crore (₹2,118 crore). Sequentially, however, both the net profit and revenue from operations declined. The company, which specialises in generic APIs, custom synthesis and nutraceuticals, had for the March quarter posted ₹662 crore net profit and ₹2,585 crore revenue from operations. Divi's shares on Wednesday closed 4.29% lower to ₹6,134.25 each on the BSE.
Business Recorder
3 days ago
- Business
- Business Recorder
Indian drugmaker Divi's misses June-quarter profit view on weak US pricing
India's Divi's Laboratories reported first-quarter profit below estimates on Wednesday, as manufacturers producing generic drugs continued to be negatively impacted by pricing pressures in the key U.S. market, sending shares down 3.3%. The Hyderabad-based company's consolidated net profit rose 26.7% to 5.45 billion rupees ($62 million) for the quarter ended June 30. Analysts, on average, had expected 5.75 billion rupees, as per data compiled by LSEG. Indian generic drugmakers, which get a significant chunk of their revenue from the U.S., have been grappling with weak pricing amid stiff competition in the region. Divi's, one of India's largest manufacturers of active pharmaceutical ingredients (API), has flagged pricing pressure and high competition in its generics business in global markets, adding that it aims to increase its market share by launching molecules as they get off patent. APIs are key chemical components in a drug that produce the intended therapeutic effects. Divi's exports to more than 100 countries, with the U.S. and Europe being its core markets The company's shares were down 2.5% before the news, in tandem with the rest of the pharma stocks on U.S. President Donald Trump's potential tariff threat. India's Pidilite posts higher quarterly profit on strong demand; announces bonus issue The drugmaker's peers Cipla and Dr Reddy's also reported subdued June-quarter sales in the U.S. Revenue from operations for Divi's rose 14% to 24.10 billion rupees, also missing analysts' estimates of 24.56 billion rupees. The company is banking on demand from diabetes and weight-loss drugs manufacturers such as Eli Lilly, who cater to skyrocketing customer demand for the drug in global markets.
Time of India
3 days ago
- Business
- Time of India
Divi's Laboratories Q1 Results: Cons net profit rises 27% YoY to Rs 545 crore, revenue up 14%
Divi's Laboratories on Wednesday reported a consolidated net profit attributable to the shareholders of the company at Rs 545 crore for the first quarter ended June 2025, posting a 26.7% year-on-year (YoY) jump from a profit of Rs 430 crore reported in the year-ago quarter. The Hyderabad-based pharmaceutical major reported a consolidated revenue from operations of Rs 2,410 crore for the first quarter of FY26, up 13.8% from Rs 2,118 crore in the same period last year. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The company said its total income for the June 2025 quarter stood at Rs 2,529 crore, compared with Rs 2,197 crore in Q1 FY25. Profit before tax (PBT) for the reporting period rose to Rs 733 crore, up from Rs 604 crore in the year-ago quarter, though it was lower than the Rs 864 crore reported in the March 2025 quarter. The company also reported a forex gain of Rs 39 crore, reversing a Rs 1 crore loss in the same period last year. Live Events Stock moves and technicals At 12:13 PM IST, shares of Divi's Laboratories were trading 2.9% lower at Rs 6,225.30 on the BSE following the earnings announcement. The stock has gained 2.7% so far in 2025 but is down nearly 10% over the past month. From a technical standpoint, the stock is currently trading below six of its eight key simple moving averages (SMA), including the 5-day, 10-day, 20-day, 30-day, 50-day and 100-day SMAs, while the stock is trading above its 150-day and 200-day SMAs, indicating bullish undertones in the long-term charts. The Relative Strength Index (RSI) stands at 37.1. RSI below 30 is considered oversold, and above 70 is overbought. Meanwhile, the Moving Average Convergence Divergence (MACD) is at -62.1 and remains below the center and signal lines, reinforcing a strong bearish indicator. Also read | Swiggy vs Eternal: Which stock promises better value delivery post Q1 show?
